| Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor–secreting breast tumor vaccine: a chemotherapy … LA Emens, JM Asquith, JM Leatherman, BJ Kobrin, S Petrik, M Laiko, ... Journal of Clinical Oncology 27 (35), 5911, 2009 | 257 | 2009 |
| A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism EA Manning, JGM Ullman, JM Leatherman, JM Asquith, TR Hansen, ... Clinical Cancer Research 13 (13), 3951-3959, 2007 | 225 | 2007 |
| A STING agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice JB Foote, M Kok, JM Leatherman, TD Armstrong, BC Marcinkowski, ... Cancer immunology research 5 (6), 468-479, 2017 | 141 | 2017 |
| Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature cancer 2 (9), 891-903, 2021 | 127 | 2021 |
| Na, K-ATPase subunits as markers for epithelial-mesenchymal transition in cancer and fibrosis SA Rajasekaran, TP Huynh, DG Wolle, CE Espineda, LJ Inge, A Skay, ... Molecular cancer therapeutics 9 (6), 1515-1524, 2010 | 103 | 2010 |
| A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF–Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer G Chen, R Gupta, S Petrik, M Laiko, JM Leatherman, JM Asquith, ... Cancer immunology research 2 (10), 949-961, 2014 | 97 | 2014 |
| Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature Cancer 2 (9), 891-903, 2021 | 57 | 2021 |
| Ras Mutation Impairs Epithelial Barrier Function to a Wide Range of Nonelectrolytes JM Mullin, JM Leatherman, MC Valenzano, ER Huerta, J Verrechio, ... Molecular biology of the cell 16 (12), 5538-5550, 2005 | 49 | 2005 |
| Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma WJ Ho, L Danilova, SJ Lim, R Verma, S Xavier, JM Leatherman, ... Journal for immunotherapy of cancer 8 (1), 2020 | 43 | 2020 |
| Effects of B cell–activating factor on tumor immunity M Yarchoan, WJ Ho, A Mohan, Y Shah, T Vithayathil, J Leatherman, ... JCI insight 5 (10), 2020 | 30 | 2020 |
| Systemic inhibition of PTPN22 augments anticancer immunity WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ... The Journal of Clinical Investigation 131 (17), 2021 | 29 | 2021 |
| Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo MME Sunay, JB Foote, JM Leatherman, JP Edwards, TD Armstrong, ... International immunopharmacology 46, 112-123, 2017 | 28 | 2017 |
| Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). M Yarchoan, Q Zhu, JN Durham, N Gross, S Charmsaz, JM Leatherman, ... Journal of Clinical Oncology 39 (3_suppl), 335-335, 2021 | 25 | 2021 |
| Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments DJ Zabransky, L Danilova, JM Leatherman, TY Lopez‐Vidal, J Sanchez, ... Hepatology 77 (5), 1566-1579, 2023 | 19 | 2023 |
| A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res. 2014; 2 … G Chen, R Gupta, S Petrik, M Laiko, JM Leatherman, JM Asquith, ... CIR-14-0058.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2014 | 19 | 2014 |
| A feasibility study of combination therapy with trastuzumab (T), cyclophosphamide (CY), and an allogeneic GM-CSF-secreting breast tumor vaccine for the treatment of HER2+ … LA Emens, R Gupta, S Petrik, M Laiko, JM Leatherman, J Levi, JM Asquith, ... Journal of Clinical Oncology 29 (15_suppl), 2535-2535, 2011 | 13 | 2011 |
| Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection D Delitto, DJ Zabransky, F Chen, ED Thompson, JW Zimmerman, ... Oncoimmunology 10 (1), 2001159, 2021 | 12 | 2021 |
| Context-dependent immunomodulatory effects of MEK inhibition are enhanced with T-cell agonist therapy L Dennison, A Ruggieri, A Mohan, J Leatherman, K Cruz, S Woolman, ... Cancer immunology research 9 (10), 1187-1201, 2021 | 11 | 2021 |
| Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials DN Sidiropoulos, GL Stein-O’Brien, L Danilova, NE Gross, S Charmsaz, ... JCI insight 7 (19), 2022 | 6 | 2022 |
| 964Mo Entinostat, Nivolumab and Ipilimumab in advanced Her2-negative breast cancer (ETCTN-9844) ETR Torres, J Leatherman, C Rafie, A Brufsky, P LoRusso, JP Eder, ... Annals of Oncology 32, S833, 2021 | 5 | 2021 |
